| Chad H Weaver, MD | |
|
404 W Fountain St, Albert Lea, MN 56007 | |
| (507) 373-2384 | |
| Not Available |
| Full Name | Chad H Weaver |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 15 Years |
| Location | 404 W Fountain St, Albert Lea, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235367202 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 53511 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Winona Health Services | Winona, MN | Hospital |
| Gundersen Lutheran Medical Center | La crosse, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Winona Health Services | 8527977420 | 101 |
News Archive
The COVID-19 pandemic has had an adverse impact on the global economy. Researchers around the globe have been working hard to find ways to stop the spread of the disease either in the form of drugs or SOP changes that revolve around guidelines given by the WHO for maintaining hygiene and social distancing norms.
Three-quarters of youths with type 1 diabetes were found to have insufficient levels of vitamin D, according to a study by researchers at the Joslin Diabetes Center - findings that suggest children with the disease may need vitamin D supplementation to prevent bone fragility later in life.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
AMAG Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.
An unusual type of antibiotic being developed by chemists at Notre Dame University shows promise in defeating deadly "superbugs" - highly drug-resistant staph bacteria that are an increasing source of hospital-based infections.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
The COVID-19 pandemic has had an adverse impact on the global economy. Researchers around the globe have been working hard to find ways to stop the spread of the disease either in the form of drugs or SOP changes that revolve around guidelines given by the WHO for maintaining hygiene and social distancing norms.
Three-quarters of youths with type 1 diabetes were found to have insufficient levels of vitamin D, according to a study by researchers at the Joslin Diabetes Center - findings that suggest children with the disease may need vitamin D supplementation to prevent bone fragility later in life.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
AMAG Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.
An unusual type of antibiotic being developed by chemists at Notre Dame University shows promise in defeating deadly "superbugs" - highly drug-resistant staph bacteria that are an increasing source of hospital-based infections.
› Verified 1 days ago
| Entity Name | Winona Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295789352 PECOS PAC ID: 8527977420 Enrollment ID: O20040106000260 |
News Archive
The COVID-19 pandemic has had an adverse impact on the global economy. Researchers around the globe have been working hard to find ways to stop the spread of the disease either in the form of drugs or SOP changes that revolve around guidelines given by the WHO for maintaining hygiene and social distancing norms.
Three-quarters of youths with type 1 diabetes were found to have insufficient levels of vitamin D, according to a study by researchers at the Joslin Diabetes Center - findings that suggest children with the disease may need vitamin D supplementation to prevent bone fragility later in life.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
AMAG Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.
An unusual type of antibiotic being developed by chemists at Notre Dame University shows promise in defeating deadly "superbugs" - highly drug-resistant staph bacteria that are an increasing source of hospital-based infections.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
The COVID-19 pandemic has had an adverse impact on the global economy. Researchers around the globe have been working hard to find ways to stop the spread of the disease either in the form of drugs or SOP changes that revolve around guidelines given by the WHO for maintaining hygiene and social distancing norms.
Three-quarters of youths with type 1 diabetes were found to have insufficient levels of vitamin D, according to a study by researchers at the Joslin Diabetes Center - findings that suggest children with the disease may need vitamin D supplementation to prevent bone fragility later in life.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
AMAG Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.
An unusual type of antibiotic being developed by chemists at Notre Dame University shows promise in defeating deadly "superbugs" - highly drug-resistant staph bacteria that are an increasing source of hospital-based infections.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chad H Weaver, MD 404 W Fountain St, Albert Lea, MN 56007-2437 Ph: (507) 373-2384 | Chad H Weaver, MD 404 W Fountain St, Albert Lea, MN 56007 Ph: (507) 373-2384 |
News Archive
The COVID-19 pandemic has had an adverse impact on the global economy. Researchers around the globe have been working hard to find ways to stop the spread of the disease either in the form of drugs or SOP changes that revolve around guidelines given by the WHO for maintaining hygiene and social distancing norms.
Three-quarters of youths with type 1 diabetes were found to have insufficient levels of vitamin D, according to a study by researchers at the Joslin Diabetes Center - findings that suggest children with the disease may need vitamin D supplementation to prevent bone fragility later in life.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
AMAG Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.
An unusual type of antibiotic being developed by chemists at Notre Dame University shows promise in defeating deadly "superbugs" - highly drug-resistant staph bacteria that are an increasing source of hospital-based infections.
› Verified 1 days ago
Dr. Brian Gerard Zogg, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2718 Ekko Ave, Albert Lea, MN 56007 Phone: 507-373-2270 Fax: 507-373-0363 |